It's been a tough month or so for AstraZeneca, its share price sliding 24 per cent from a two-year high in late January.
IC TIP:
Hold
at
2240p
The drugs giant failed to get its neurological disorder drug, Seroquel, approved by US regulators for use by adults with anxiety disorders. Also, evidence has emerged that physicians in Japan were warned of Seroquel's links to diabetes, but that those warnings didn't appear on the US labelling. The bad news has been slightly offset by the registration of Astra's constrictive obstructive pulmonary disease (otherwise known as smoker's lungs) treatment, Symbicort, in the US. However this launch had been well-flagged.
